ArticleInternational journal of nanomedicine2026
PVP-Stabilized Ag@SiO
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Usnic acid (UA) is a lichen-derived metabolite with recognized anticancer, anti-inflammatory, and antibacterial properties; however, its clinical application is limited by poor aqueous solubility and dose-dependent toxicity. This study aimed to develop a multifunctional nanosystem to improve UA aqueous dispersibility and efficacy against breast cancer cells in vitro. Methods: A nanosystem consisting of a silver core-silica shell coated with polyvinylpyrrolidone (PVP) and conjugated UA (Ag@SiO Results: The developed nanostructures exhibited a stable core-shell architecture, uniform particle size (~200 nm), and enhanced hydrophilicity, resulting in improved aqueous dispersibility and sustained UA release. Nanoencapsulation significantly enhanced UA's anticancer activity against breast cancer cells in vitro while maintaining lower toxicity toward normal cells. Mechanistically, Ag@SiO Conclusion: Ag@SiO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.